Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Versant Venture Management, LLC (CIK 1560009) reported $162.6M across 8 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: GLUE ($77.0M, 47.34%), IPSC ($29.8M, 18.33%), JBIO ($22.0M, 13.55%), LENZ ($15.1M, 9.28%), CTNM ($8.9M, 5.47%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | GLUE | Monte Rosa Therapeutics, Inc. | $77.0M | 47.34% | 3.2M | Hold |
| 2 | IPSC | Century Therapeutics, Inc. | $29.8M | 18.33% | 12.2M | Hold |
| 3 | JBIO | Jade Biosciences, Inc. | $22.0M | 13.55% | 991,783 | Trimmed |
| 4 | LENZ | Lenz Therapeutics, Inc. | $15.1M | 9.28% | 2.7M | Hold |
| 5 | CTNM | Contineum Therapeutics, Inc. | $8.9M | 5.47% | 542,628 | Hold |
| 6 | CRSP | CRISPR Therapeutics AG | $8.1M | 4.99% | 148,831 | Hold |
| 7 | SKYE | Skye Bioscience, Inc. | $1.4M | 0.86% | 2.0M | Hold |
| 8 | TPST | Tempest Therapeutics, Inc. | $299,447 | 0.18% | 269,772 | Hold |
Source: SEC Form 13F filings · as of 2026-06-30